Cost-effectiveness of expanded antiviral treatment for chronic hepatitis B virus infection in China: an economic evaluation.

Lancet Reg Health West Pac · 2023 · PMC10326688 · PMID 37424693

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Compared to the 20% coverage strategy, increased coverages showed a decreasing trend in ICER from US$ 114,832/QALY to US$ 130,814/QALY gained by 2030, and US$ 29,069/QALY to US$ 31,546/QALY gained by 2040, respectively.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.